5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The North America Nuclear Medicine Market is segmented by Diagnostics, Therapeutics, Applications (Cardiology, Neurology, Oncology, and Other Applications), and Geography.
2018 - 2026
North America Nuclear Imaging Market expected to witness significant growth owing to the technological advancements, rising burden of diseases, and adoption of nuclear medicine in therapeutics as well as diagnostics.
For instance, the volume of PET procedures in the United States is about 1.5 million per year. According to the National Oncology PET Registry, about 84% of more than 1,600 PET facilities in the United States have PET/CT systems.
In 2018, the US FDA approved NorthStar Medical Radioisotopes RadioGenix System (Technetium Tc 99m Generator) for the Non-uranium Sourced Molybdenum-99 (Mo-99) Production of Imaging Isotope Technetium-99m (Tc-99m). It is the most widely used imaging agent, and thus, with its approval NorthStar, has begin providing its customers with a reliable and eco-friendly supply of the Mo-99 radioisotope for the United States.
Thus, the emergence of molecular imaging, with new radiopharmaceuticals and new technologies, is likely to result in continued growth in the coming decades.
Nuclear medicine falls under the field of molecular imaging, which involves the use of a very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by special types of cameras attached to the computer, which in turn, provide very precise pictures of the area of the body examined.
|By Product Type|
Report scope can be customized per your requirements. Click here.
Nuclear medicine can be used to treat various medical conditions, especially cancer, by using radiation to weaken or destroy the targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used in clinical role in oncology, with fluorine-18 as the tracer, as it is proven to be the most accurate non-invasive method of detecting and evaluating most cancers.
External irradiation (also called as teletherapy) is known as gamma knife radiosurgery and involves focusing gamma radiation from 201 sources of Cobalt-60 on a precise area of the brain with a cancerous tumor.
Nuclear medicine is proven to be effective in oncology in several roles, spanning through the course of the disease, including the characterization of a mass, staging, restaging, monitoring of therapeutic response.
To understand key trends, Download Sample Report
There is high competition among the players in the North America nuclear medicine market. However, this competition is not by virtue of competitive pricing or product differentiation. For instance, in April 2017, IBA Molecular and Mallinckrodt Nuclear Medicine LLC united to create Curium, a world-class provider in nuclear imaging.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
4.2.2 Increasing Demand for Image Guided Procedures and Diagnostics
4.3 Market Restraints
4.3.1 High Cost of the Diagnostic and Therapeutic Equipment and Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product Type
22.214.171.124 Singple Photon Emission Computed Tomography (SPECT)
126.96.36.199 Photon Emission Tomography (PET)
188.8.131.52 Alpha Emitters
184.108.40.206 Beta Emitters
5.2 By Application
5.2.4 Other Applications
5.3.1 North America
220.127.116.11 United States
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Siemens AG
6.1.2 GE Healthcare
6.1.3 Cardinal Health
6.1.4 Sotera Health (Nordion Inc.)
6.1.5 Curium Pharma
6.1.6 Cambridge Isotope Laboratories Inc.
6.1.7 Triad Isotopes
6.1.8 Advanced Accelerator Applications
6.1.9 Lantheus Medical Imaging, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS